{"filing":{"accession_number":"0001213900-26-111190","cik":"0002007702","ticker":"HKPD","company_name":"Cellyan Biotechnology Co., Ltd","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"ea0308948-6k_cellyan.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007702/000121390026111190/ea0308948-6k_cellyan.htm"},"events":[{"id":36605,"run_id":33752,"accession_number":"0001213900-26-111190","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The press release announces a 1-for-20 reverse stock split effective October 26, 2026, explicitly stating the action is \"primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" The disclosure acknowledges delisting risk by noting \"there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq's continued listing requirement thereafter,\" which is a material disclosure of compliance failure and delisting threat.","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41071,"accession_number":"0001213900-26-111190","item_number":"EX-99.1","item_title":"ea030894801ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces a 1-for-20 reverse stock split effective October 26, 2026, explicitly stating the action is \"primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" The disclosure acknowledges delisting risk by noting \"there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq's continued listing requirement thereafter,\" which is a material disclosure of compliance failure and delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T12:01:37.590851+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41071,"accession_number":"0001213900-26-111190","item_number":"EX-99.1","item_title":"ea030894801ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces a 1-for-20 reverse stock split effective October 26, 2026, explicitly stating the action is \"primarily intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.\" The disclosure acknowledges delisting risk by noting \"there can be no assurance that the Company will regain compliance with such requirement within the applicable compliance period or maintain compliance with Nasdaq's continued listing requirement thereafter,\" which is a material disclosure of compliance failure and delisting threat.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T12:01:37.590851+00:00","company_name":"Cellyan Biotechnology Co., Ltd","ticker":"HKPD","filing_date":"2026-10-21"}]}